Guard Therapeutics: Positive Results
Redeye reiterate our valuation on Guard Therapeutics (ticker: GUARD) following positive news. Today Guard Therapeutics presented follow-up data on its phase 1A, single ascending dose (SAD) study. The results are positive and somewhat unexpected.